BioInvent International

• NCT04752826

  Phase 1/2, Recruiting, 250 people, Feb 12, 2021

• A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

  Phase 1/2, Recruiting, 140 people, Jun 27, 2018

Sources: clinicaltrials.gov